Antimicrobial Agents and Chemotherapy, August 2001, p. 2405-2405, Vol. 45, No. 8
Circulating Metabolites of the Human Immunodeficiency
Virus Protease Inhibitor Nelfinavir in Humans: Structural
Identification, Levels in Plasma, and Antiviral Activities
Pfizer Global Research and Development, La Jolla, California, and
Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka
569, Japan
Volume 45, no. 4, p. 1086-1093, 2001. Page 1090, column 1, lines
1 to 5: "did not show any ... or its metabolites" should read "showed no significant differences in exposure to either the parent drug or its metabolites between the first dose and steady state (Table
3); however, this analysis was not designed or powered to rule out
modest changes in clearance or exposure, and the trend for increased
M8-to-nelfinavir concentration ratio on day 28 may reflect modest
induction of metabolism during multiple dosing."
0066-4804/01 DOI:
Copyright © 2001, American Society for Microbiology. All rights reserved.
AUTHOR'S CORRECTION
Antimicrobial Agents and Chemotherapy, August 2001, p. 2405-2405, Vol. 45, No. 8
0066-4804/01 DOI:
Copyright © 2001, American Society for Microbiology. All rights reserved.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»